Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Personalized Cancer Vaccines Demonstrate Potential in Melanoma Studies

Personalized Cancer Vaccines Demonstrate Potential in Melanoma Studies

Jul 05, 2017
|
staff reporter

NEW YORK (GenomeWeb) – A pair of new studies is pointing to the potential of personalized anti-cancer vaccine strategies in individuals with advanced melanoma.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Finds a Whole Bunch

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Away From the Field

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

PNAS Studies Look at Bacterial Detection Probes, Cholera Culprit Evolution in Environment, More

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

In a Different Lab

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Sequencing

  1. COVID-19 Host Susceptibility Studies Ramp Up Internationally

  2. SARS-CoV-2-Related Coronaviruses Found in Pangolins

  3. Stanford Team Debuts New Liquid Biopsy Lung Cancer Screening Method

    Premium

  4. UK COVID-19 Sequencing Consortium to Reveal Viral Spread, Evolution

  5. Rockefeller-Led Team Launches Initiative to Study COVID-19 Genetic Vulnerability

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.